%0 Journal Article
%T Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients ¨C study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 Study
%A Claus Fristrup
%A Martin Graversen
%A Michael Bau Mortensen
%A Per Pfeiffer
%A S£¿nke Detlefsen
%J Archive of "Pleura and Peritoneum".
%D 2018
%R 10.1515/pp-2018-0107
%X Peritoneal metastasis (PM) is the second most common site of recurrence in colon cancer (CC) patients and accounts for approximately one-third of all recurrences. Patients with T4 or intraperitoneal perforated colon cancers have an increased risk of developing PM, and since manifest PM is difficult to treat, high-risk patients should be offered prophylactic treatment. Here, we propose a study of adjuvant oxaliplatin administered as pressurized intraperitoneal aerosol chemotherapy (PIPAC OX) in patients with high-risk colon cancer (T4, perforated tumors, ovarian metastasis)
%K adjuvant PIPAC
%K high-risk
%K colon cancer
%K resection
%K peritoneal metastasis.
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404996/